(GEHC) GE HealthCare Technologies - Overview
Stock: Imaging, Ultrasound, Monitoring, Contrast, Radiopharmaceuticals
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.22% |
| Yield on Cost 5y | 0.23% |
| Yield CAGR 5y | 24.72% |
| Payout Consistency | 100.0% |
| Payout Ratio | 3.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.4% |
| Relative Tail Risk | -8.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.21 |
| Alpha | -30.12 |
| Character TTM | |
|---|---|
| Beta | 1.321 |
| Beta Downside | 1.617 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.35% |
| CAGR/Max DD | 0.10 |
Description: GEHC GE HealthCare Technologies December 17, 2025
GE HealthCare Technologies Inc. (NASDAQ: GEHC) develops, manufactures, and markets medical imaging, advanced visualization, patient-care, and pharmaceutical-diagnostic products and digital solutions across the U.S., Canada, and global markets. The business is organized into four segments: Imaging (CT, MR, X-ray, molecular imaging, womens health), Advanced Visualization Solutions (ultrasound, interventional and surgical guidance), Patient Care Solutions (monitoring, cardiology, consumables, anesthesia, maternal-infant care), and Pharmaceutical Diagnostics (contrast media and radiopharmaceuticals). The company, renamed from GE Healthcare Holding LLC in December 2022, is headquartered in Chicago.
Key recent data points: FY 2023 revenue was ≈ $19.2 billion, with the Imaging segment contributing roughly 55 % of total sales; operating margin stood at 12 % and free cash flow at $2.5 billion. Growth is being driven by AI-enabled imaging workflows, expanding outpatient imaging volumes, and an aging population that fuels demand for diagnostic services. However, margin pressure from supply-chain constraints and evolving reimbursement policies remains a material risk.
For a deeper quantitative dive, consider reviewing GE HC’s detailed financials and valuation metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 2.22b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.13 > 1.0 |
| NWC/Revenue: 8.99% < 20% (prev 8.22%; Δ 0.77% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.85b > Net Income 2.22b |
| Net Debt (6.74b) to EBITDA (3.80b): 1.77 < 3 |
| Current Ratio: 1.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (457.0m) vs 12m ago -0.44% < -2% |
| Gross Margin: 40.80% > 18% (prev 0.41%; Δ 4039 % > 0.5%) |
| Asset Turnover: 57.86% > 50% (prev 57.77%; Δ 0.09% > 0%) |
| Interest Coverage Ratio: 7.24 > 6 (EBITDA TTM 3.80b / Interest Expense TTM 446.0m) |
Altman Z'' 1.52
| A: 0.05 (Total Current Assets 11.89b - Total Current Liabilities 10.07b) / Total Assets 36.13b |
| B: 0.13 (Retained Earnings 4.71b / Total Assets 36.13b) |
| C: 0.09 (EBIT TTM 3.23b / Avg Total Assets 34.99b) |
| D: 0.14 (Book Value of Equity 3.56b / Total Liabilities 25.91b) |
| Altman-Z'' Score: 1.52 = BB |
Beneish M -2.96
| DSRI: 1.06 (Receivables 4.68b/4.28b, Revenue 20.25b/19.56b) |
| GMI: 1.01 (GM 40.80% / 41.33%) |
| AQI: 0.95 (AQ_t 0.59 / AQ_t-1 0.62) |
| SGI: 1.04 (Revenue 20.25b / 19.56b) |
| TATA: 0.01 (NI 2.22b - CFO 1.85b) / TA 36.13b) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of GEHC shares?
Over the past week, the price has changed by -3.80%, over one month by -5.22%, over three months by +1.85% and over the past year by -10.16%.
Is GEHC a buy, sell or hold?
- StrongBuy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GEHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 92 | 16.8% |
| Analysts Target Price | 92 | 16.8% |
| ValueRay Target Price | 79.1 | 0.5% |
GEHC Fundamental Data Overview January 27, 2026
P/E Forward = 16.835
P/S = 1.7989
P/B = 3.6362
P/EG = 2.3888
Revenue TTM = 20.25b USD
EBIT TTM = 3.23b USD
EBITDA TTM = 3.80b USD
Long Term Debt = 8.28b USD (from longTermDebt, last quarter)
Short Term Debt = 2.14b USD (from shortTermDebt, last quarter)
Debt = 10.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.74b USD (from netDebt column, last quarter)
Enterprise Value = 43.16b USD (36.42b + Debt 10.74b - CCE 4.00b)
Interest Coverage Ratio = 7.24 (Ebit TTM 3.23b / Interest Expense TTM 446.0m)
EV/FCF = 30.83x (Enterprise Value 43.16b / FCF TTM 1.40b)
FCF Yield = 3.24% (FCF TTM 1.40b / Enterprise Value 43.16b)
FCF Margin = 6.92% (FCF TTM 1.40b / Revenue TTM 20.25b)
Net Margin = 10.95% (Net Income TTM 2.22b / Revenue TTM 20.25b)
Gross Margin = 40.80% ((Revenue TTM 20.25b - Cost of Revenue TTM 11.98b) / Revenue TTM)
Gross Margin QoQ = 38.69% (prev 39.61%)
Tobins Q-Ratio = 1.19 (Enterprise Value 43.16b / Total Assets 36.13b)
Interest Expense / Debt = 1.03% (Interest Expense 111.0m / Debt 10.74b)
Taxrate = 27.84% (179.0m / 643.0m)
NOPAT = 2.33b (EBIT 3.23b * (1 - 27.84%))
Current Ratio = 1.18 (Total Current Assets 11.89b / Total Current Liabilities 10.07b)
Debt / Equity = 1.08 (Debt 10.74b / totalStockholderEquity, last quarter 9.99b)
Debt / EBITDA = 1.77 (Net Debt 6.74b / EBITDA 3.80b)
Debt / FCF = 4.81 (Net Debt 6.74b / FCF TTM 1.40b)
Total Stockholder Equity = 9.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.33% (Net Income 2.22b / Total Assets 36.13b)
RoE = 23.74% (Net Income TTM 2.22b / Total Stockholder Equity 9.34b)
RoCE = 18.33% (EBIT 3.23b / Capital Employed (Equity 9.34b + L.T.Debt 8.28b))
RoIC = 12.32% (NOPAT 2.33b / Invested Capital 18.90b)
WACC = 8.49% (E(36.42b)/V(47.16b) * Re(10.78%) + D(10.74b)/V(47.16b) * Rd(1.03%) * (1-Tc(0.28)))
Discount Rate = 10.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.11%
[DCF Debug] Terminal Value 75.82% ; FCFF base≈1.52b ; Y1≈1.47b ; Y5≈1.47b
Fair Price DCF = 37.26 (EV 23.71b - Net Debt 6.74b = Equity 16.97b / Shares 455.5m; r=8.49% [WACC]; 5y FCF grow -4.08% → 2.90% )
EPS Correlation: -19.01 | EPS CAGR: -16.19% | SUE: 0.31 | # QB: 0
Revenue Correlation: 71.74 | Revenue CAGR: 3.09% | SUE: 0.73 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.99 | Chg30d=-0.004 | Revisions Net=-2 | Analysts=13
EPS next Year (2026-12-31): EPS=4.93 | Chg30d=-0.006 | Revisions Net=+0 | Growth EPS=+8.2% | Growth Revenue=+4.3%